SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026PRNewsWire · 4 days ago
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.PRNewsWire · Aug 25, 2026
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICERPRNewsWire · Aug 19, 2026
Sera Prognostics Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 12, 2026
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research · Aug 12, 2026Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.15 | -$0.18 | Miss |
| May 6, 2026 | -$0.16 | -$0.17 | Miss |
| Mar 18, 2026 | -$0.17 | -$0.16 | Beat |
| Nov 13, 2025 | -$0.19 | -$0.16 | Beat |
| Aug 6, 2025 | -$0.21 | -$0.16 | Beat |
| May 7, 2025 | -$0.24 | -$0.20 | Beat |